{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:43:53Z","timestamp":1787010233715,"version":"build-2736575974"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:p>\n                    Asparaginase is an established chemotherapeutic agent for acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LL) treatment. Pegylated asparaginase (PEG-Asp) is first-line but may lead to allergic reactions in \u223c30% of recipients, leading to substitution by\n                    <jats:italic toggle=\"yes\">Erwinia<\/jats:italic>\n                    -derived asparaginase. Studies demonstrate mixed results on the impact of universal premedication on the incidence of infusion reactions. Our center adopted universal premedication with H1 and H2 antagonists and nadir serum asparaginase activity (SAA) level monitoring in 2019. We assessed the impact of universal premedication on hypersensitivity reactions. We reviewed 107 pediatric ALL\/LL patients who received 355 PEG-Asp doses, comparing the frequency of hypersensitivity reactions before universal premedication (PM\n                    <jats:sup>\u2212<\/jats:sup>\n                    ) from 2016 to 2018 and after implementation (PM\n                    <jats:sup>+<\/jats:sup>\n                    ) from 2019 to 2021. No significant difference in reactions was observed between PM\n                    <jats:sup>\u2212<\/jats:sup>\n                    (13 reactions, 27%) and PM\n                    <jats:sup>+<\/jats:sup>\n                    (10 reactions, 17%) patients across all risk stratifications (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    =0.25) or in the severity of reactions. SAA monitoring identified 2 patients (4%) with silent inactivation. The number of\n                    <jats:italic toggle=\"yes\">Erwinia<\/jats:italic>\n                    doses administered between groups did not differ significantly (325 vs. 210,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    =0.13). Universal premedication with H1 and H2 antagonists did not impact the number or grade of hypersensitivity reactions to PEG-Asp. We suggest SAA monitoring for patients receiving PEG-Asp to identify silent inactivations.\n                  <\/jats:p>","DOI":"10.1097\/mph.0000000000003164","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T14:02:39Z","timestamp":1770818559000},"page":"69-74","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Use of Universal Premedication in the Prevention of Allergic Reactions to PEGylated-Asparaginase in Children and Adolescents With Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma"],"prefix":"10.1097","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1215-5205","authenticated-orcid":false,"given":"Andr\u00e9s F.","family":"Fajardo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Cox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"MacDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uma","family":"Athale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,2,11]]},"reference":[{"key":"R1-20260225","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1056\/NEJMra1400972","article-title":"Acute lymphoblastic leukemia in children","volume":"373","author":"Hunger","year":"2015","journal-title":"N Engl J Med"},{"key":"R2-20260225","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1182\/blood.V97.5.1211","article-title":"Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01","volume":"97","author":"Silverman","year":"2001","journal-title":"Blood"},{"key":"R3-20260225","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1200\/JCO.19.03024","article-title":"Impact of asparaginase discontinuation on outcome in childhood acute lymphoblastic leukemia(ALL): a report from the Children\u2019s Oncology Group (COG)","volume":"38","author":"Gupta","year":"2019","journal-title":"J Clin Oncol"},{"key":"R4-20260225","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1097\/MPH.0b013e3181e6f003","article-title":"Tolerability and efficacy of L-asparaginase therapy in pediatric patients with acute lymphoblastic leukemia","volume":"32","author":"Raetz","year":"2010","journal-title":"J Pediatr Hematol Oncol"},{"key":"R5-20260225","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1188\/10.CJON.E10-E21","article-title":"Infusion reactions: diagnosis, assessment, and management","volume":"14","author":"Vogel","year":"2010","journal-title":"Clin J Oncol Nurs"},{"key":"R6-20260225","first-page":"99","article-title":"Antibody response to Escherichia coli L-asparaginase. Prognostic significance and clinical utility of antibody measurement","volume":"8","author":"Cheung","year":"1986","journal-title":"Am J Pediatr Hematol Oncol"},{"key":"R7-20260225","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/00043426-200404000-00002","article-title":"Asparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblastic leukemia: Children\u2019s Cancer Group study CCG-1961","volume":"26","author":"Panosyan","year":"2004","journal-title":"J Pediatr Hematol Oncol"},{"key":"R8-20260225","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.3109\/10428194.2014.1003056","article-title":"Asparaginase pharmacokinetics and implications of therapeutic drug monitoring","volume":"56","author":"Asselin","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"R9-20260225","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1007\/s12325-021-01999-x","article-title":"The role of cetirizine in the changing landscape of IV antihistamines: a narrative review","volume":"39","author":"Blaiss","year":"2022","journal-title":"Adv Ther"},{"key":"R10-20260225","doi-asserted-by":"crossref","first-page":"e27797","DOI":"10.1002\/pbc.27797","article-title":"Universal premedication and therapeutic drug monitoring for asparaginase-based therapy prevents infusion-associated acute adverse events and drug substitutions","volume":"66","author":"Cooper","year":"2019","journal-title":"Pediatr Blood Cancer"},{"key":"R11-20260225","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.12688\/f1000research.19298.1","article-title":"Retrospective cohort study monitoring PEG-asparaginase activity in acute lymphoblastic leukemia patients with and without premedication","volume":"8","author":"Losasso","year":"2019","journal-title":"F1000Res"},{"key":"R12-20260225","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.3109\/10428194.2015.1105369","article-title":"Allergic reactions associated with pegaspargase in adults","volume":"57","author":"Chang","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"R13-20260225","first-page":"5574","article-title":"Use of premedication prior to asparaginase (ASNase) administration in pediatric acute lymphoblastic leukemia (ALL): effect on treatment completion rate","volume":"130","author":"Bernard","year":"2017","journal-title":"Blood"},{"key":"R14-20260225","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1182\/blood-2018-10-881961","article-title":"A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403","volume":"133","author":"Stock","year":"2019","journal-title":"Blood"},{"key":"R15-20260225","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1080\/10428194.2019.1608530","article-title":"A single-center multidisciplinary approach to managing the global Erwinia asparaginase shortage","volume":"60","author":"Marini","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"R16-20260225","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1182\/blood-2020-143248","article-title":"Premedication and longer infusion time do not reduce the incidence of hypersensitivity reactions to pegaspargase","volume":"136","author":"Hughes","year":"2020","journal-title":"Blood"},{"key":"R17-20260225","first-page":"232","article-title":"Efficacy of a standardized premedication and therapeutic drug monitoring protocol for pegaspargase to prevent hypersensitivity reactions","volume":"27","author":"Babcock","year":"2022","journal-title":"J Pediatr Pharmacol Ther"},{"key":"R18-20260225","doi-asserted-by":"crossref","first-page":"e30716","DOI":"10.1002\/pbc.30716","article-title":"Lack of benefit from premedication for pegylated asparaginase during pediatric acute lymphoblastic leukemia\/lymphoma therapy: a side-by-side comparison","volume":"71","author":"Menig","year":"2024","journal-title":"Pediatr Blood Cancer"},{"key":"R19-20260225","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1200\/JCO.2008.18.6916","article-title":"Pediatric-inspired therapy in adults with Philadelphia chromosome\u2013negative acute lymphoblastic leukemia: the GRAALL-2003 study","volume":"27","author":"Huguet","year":"2009","journal-title":"J Clin Oncol"},{"key":"R20-20260225","first-page":"55","article-title":"Asparaginase in the treatment of acute lymphoblastic leukemia in adults: current evidence and place in therapy","volume":"12","author":"Juluri","year":"2022","journal-title":"Blood Lymphat Cancer"},{"key":"R21-20260225","doi-asserted-by":"crossref","first-page":"e000858","DOI":"10.1136\/esmoopen-2020-000858","article-title":"Managing toxicities with asparaginase-based therapies in adult ALL: summary of an ESMO Open\u2013Cancer Horizons roundtable discussion","volume":"5","author":"Burke","year":"2020","journal-title":"ESMO Open"},{"key":"R22-20260225","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1177\/1078155219838316","article-title":"Optimizing pegylated asparaginase use: an institutional guideline for dosing, monitoring, and management","volume":"26","author":"Bade","year":"2020","journal-title":"J Oncol Pharm Pract"},{"key":"R23-20260225","doi-asserted-by":"crossref","first-page":"e27797","DOI":"10.1002\/pbc.27797","article-title":"Universal premedication and therapeutic drug monitoring for asparaginase-based therapy prevents infusion-associated acute adverse events and drug substitutions","volume":"66","author":"Cooper","year":"2019","journal-title":"Pediatr Blood Cancer"},{"key":"R24-20260225","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S1470-2045(12)70600-9","article-title":"Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial","volume":"14","author":"Vora","year":"2013","journal-title":"Lancet Oncol"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000003164","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T15:01:07Z","timestamp":1772031667000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000003164"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,11]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000003164","relation":{},"ISSN":["1077-4114","1536-3678"],"issn-type":[{"value":"1077-4114","type":"print"},{"value":"1536-3678","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,11]]},"assertion":[{"value":"2025-07-14","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-17","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}